Mostrar el registro sencillo del ítem
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load
| dc.rights.license | open | en_US |
| dc.contributor.author | GONCALVES, A. | |
| dc.contributor.author | BERTRAND, J. | |
| dc.contributor.author | KE, R. | |
| dc.contributor.author | COMETS, E. | |
| dc.contributor.author | DE LAMBALLERIE, X. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MALVY, Denis
ORCID: 0000-0003-1948-9355 IDREF: 148480993 | |
| dc.contributor.author | PIZZORNO, A. | |
| dc.contributor.author | TERRIER, O. | |
| dc.contributor.author | ROSA CALATRAVA, M. | |
| dc.contributor.author | MENTRE, F. | |
| dc.contributor.author | SMITH, P. | |
| dc.contributor.author | PERELSON, A. S. | |
| dc.contributor.author | GUEDJ, J. | |
| dc.date.accessioned | 2021-03-18T10:55:29Z | |
| dc.date.available | 2021-03-18T10:55:29Z | |
| dc.date.issued | 2020-09 | |
| dc.identifier.issn | 2163-8306 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/26734 | |
| dc.description.abstractEn | We modeled the viral dynamics of 13 untreated patients infected with SARS-CoV-2 to infer viral growth parameters and predict the effects of antiviral treatments. In order to reduce peak viral load by more than 2 logs, drug efficacy needs to be greater than 90% if treatment is administered after symptom onset; an efficacy of 60% could be sufficient if treatment is initiated before symptom onset. Given their pharmacokinetic/pharmacodynamic properties, current investigated drugs may be in a range of 6-87% efficacy. They may help control virus if administered very early, but may not have a major effect in severe patients. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
| dc.title.en | Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load | |
| dc.title.alternative | CPT Pharmacometrics Syst Pharmacol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1002/psp4.12543 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 32558354 | en_US |
| bordeaux.journal | CPT: Pharmacometrics and Systems Pharmacology | en_US |
| bordeaux.page | 509-514 | en_US |
| bordeaux.volume | 9 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - U1219 | en_US |
| bordeaux.issue | 9 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | IDLIC | en_US |
| bordeaux.team | HEALTHY_BPH | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=CPT:%20Pharmacometrics%20and%20Systems%20Pharmacology&rft.date=2020-09&rft.volume=9&rft.issue=9&rft.spage=509-514&rft.epage=509-514&rft.eissn=2163-8306&rft.issn=2163-8306&rft.au=GONCALVES,%20A.&BERTRAND,%20J.&KE,%20R.&COMETS,%20E.&DE%20LAMBALLERIE,%20X.&rft.genre=article |
